UBS Group
EUCR

UBS Group’s Eucrates Biomedical Acquisition Corp. Ordinary Shares EUCR Stock Holding History

UBS Group’s Portfolio EUCR Stock Details EUCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3,483
Closed -$34.8K – 11199
2022
Q4 		$34.8K Sell
3,483
-434
-11% -$4.33K ﹤0.01% 7091
2022
Q3 		$39K Buy
3,917
+1,722
+78% +$17.2K ﹤0.01% 6599
2022
Q2 		$22K Sell
2,195
-337
-13% -$3.33K ﹤0.01% 6785
2022
Q1 		$25K Buy
2,532
+2,141
+548% +$21K ﹤0.01% 7216
2021
Q4 		$4K Sell
391
-2,109
-84% -$20.7K ﹤0.01% 9590
2021
Q3 		$24K Sell
2,500
-1,299
-34% -$12.7K ﹤0.01% 6992
2021
Q2 		$37K Sell
3,799
-155
-4% -$1.52K ﹤0.01% 6731
2021
Q1 		$39K Buy
+3,954
New +$40.6K ﹤0.01% 6792

Other funds holding EUCR

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SIA
SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group's EUCR Position: Q1 2023 in Review

UBS Group sold out of Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) in Q1 2023, closing a stake of 3,483 shares — an estimated $34.8K sold.

UBS Group first reported a position in EUCR in Q1 2021 and held it in 8 quarters. The position peaked at $39K in Q3 2022. 4 funds tracked by Wall St. Rank hold EUCR as of Q1 2023.

  • UBS Group reported no remaining Eucrates Biomedical Acquisition Corp. Ordinary Shares position as of Q1 2023 after selling out during the quarter.
  • UBS Group sold 3,483 Eucrates Biomedical Acquisition Corp. Ordinary Shares shares in Q1 2023, an estimated $34.8K.
  • UBS Group first reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares in Q1 2021 and held it in 8 quarters.
  • UBS Group's Eucrates Biomedical Acquisition Corp. Ordinary Shares position peaked at $39K in Q3 2022.
  • 4 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Ordinary Shares as of Q1 2023.

Based on UBS Group's 13F filing for Q1 2023, filed 12 May 2023.